Pfizer

Junior Investigator Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research

Epidemiology, basic science, early diagnosis and treatment of ATTR-CM through research focused in the following areas:

• Epidemiologic evaluations for ATTR-CM
• Approaches for the early identification and follow up of ATTR-CM patients
• RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR-CM
• Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy)
• Longitudinal evaluations of neurologic manifestations in patients with ATTR-CM including wild type
• Mechanistic studies to advance the basic science of amyloid formation and deposition on the heart
• Characteristics of ATTR-CM in post-organ transplant patients, including natural course of disease progression

• European country specific early access program data collection

Funding: up to $75,000/year for 1 to 2 years.

https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2021-01/GMG_RFPResearch_ATTR-CM_2021Global.pdf?TDNWBFbM3bdjRfz8lQWqk3Q.OWA_oslt

Junior Investigator Transthyretin Amyloid Polyneuropathy (ATTR-PN) Research

Epidemiology, basic science and early diagnosis and treatment of ATTR-PN through research focused in the following areas:

• Epidemiologic evaluations for ATTR-PN
• Approaches for the early appropriate diagnosis of ATTR-PN patients
• Evaluation of patients with ATTR-PN presenting with a mixed phenotype
• Real world efficacy and safety of tafamidis monotherapy in the clinical setting for the management of ATTR-PN

• Mechanistic studies to advance the basic science of amyloid formation and deposition 

Funding: up to $75,000/year for 1 to 2 years.

https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2021-01/GMG_RFPResearch_ATTR-PN_2021Global.pdf?kkfgZprCPtDb_J3KowQHa9jGEu0FGmBx